tiprankstipranks
Trending News
More News >
RegenXBio (RGNX)
NASDAQ:RGNX

RegenXBio (RGNX) Stock Statistics & Valuation Metrics

Compare
913 Followers

Total Valuation

RegenXBio has a market cap or net worth of $295.19M. The enterprise value is $423.24M.
Market Cap$295.19M
Enterprise Value$423.24M

Share Statistics

RegenXBio has 50.12M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding50.12M
Owened by Insiders9.17%
Owened by Instutions23.30%

Financial Efficiency

RegenXBio’s return on equity (ROE) is -0.87 and return on invested capital (ROIC) is -62.95%.
Return on Equity (ROE)-87.46%
Return on Assets (ROA)-48.74%
Return on Invested Capital (ROIC)-62.95%
Return on Capital Employed (ROCE)-64.32%
Revenue Per Employee$236,056.657
Profits Per Employee-$643,348.442
Employee Count353
Asset Turnover0.18
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of RegenXBio is -1.69. RegenXBio’s PEG ratio is 0.07.
PE Ratio-1.69
PS Ratio4.59
PB Ratio1.47
Price to Fair Value1.47
Price to FCF-2.18
Price to Operating Cash Flow-2.21
PEG Ratio0.07

Income Statement

In the last 12 months, RegenXBio had revenue of $83.33M and earned -$227.10M in profits. Earnings per share was -$4.61.
Revenue$83.33M
Gross Profit$41.53M
Operating Income-$231.25M
Pretax Income-$227.10M
Net Income-$227.10M
EBITDA-198.23M
Earnings Per Share (EPS)-4.61

Cash Flow

In the last 12 months, operating cash flow was -$173.13M and capital expenditures -$2.44M, giving a free cash flow of -$175.56M billion.
Operating Cash Flow-$173.13M
Free Cash Flow-$175.56M
Free Cash Flow per Share-$3.50

Dividends & Yields

RegenXBio pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-45.87%
Earnings Yield-59.34%

Stock Price Statistics

Beta1.66
52-Week Price Change-67.31%
50-Day Moving Average7.11
200-Day Moving Average9.59
Relative Strength Index (RSI)41.59
Average Volume (3m)1.08M

Important Dates

RegenXBio upcoming earnings date is Apr 30, 2025, After Close.
Last Earnings DateMar 13, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date

Financial Position

RegenXBio as a current ratio of 2.69, with Debt / Equity ratio of 0.32
Current Ratio2.69
Quick Ratio2.69
Debt to Market Cap0.21
Net Debt to EBITDA-0.12
Interest Coverage Ratio-18.43

Taxes

In the past 12 months, RegenXBio has paid $1.00 in taxes.
Income Tax$1.00
Effective Tax Rate0.00%

Enterprise Valuation

RegenXBio EV to EBITDA ratio is -2.05, with an EV/FCF ratio of -2.32.
EV to Sales4.89
EV to EBITDA-2.05
EV to Free Cash Flow-2.32
EV to Operating Cash Flow-2.35

Balance Sheet

RegenXBio has $234.69M in cash and marketable securities with $82.03M in debt, giving a net cash position of -$152.65M billion.
Cash & Marketable Securities$234.69M
Total Debt$82.03M
Net Cash-$152.65M
Net Cash Per Share-$3.05
Tangible Book Value Per Share$5.24

Margins

Gross margin is 59.72%, with operating margin of -280.03%, and net profit margin of -272.54%.
Gross Margin59.72%
Operating Margin-280.03%
Pretax Margin-272.54%
Net Profit Margin-272.54%
EBITDA Margin-237.89%
EBIT Margin-257.35%

Analyst Forecast

The average price target for RegenXBio is $32.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.70
Price Target Upside455.18%
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast-7.66%
EPS Growth Forecast23.04%

Scores

Smart Score7
AI Score56
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis